[go: up one dir, main page]

WO2007146761A3 - Diaryl pyrimidinones et composés associés - Google Patents

Diaryl pyrimidinones et composés associés Download PDF

Info

Publication number
WO2007146761A3
WO2007146761A3 PCT/US2007/070676 US2007070676W WO2007146761A3 WO 2007146761 A3 WO2007146761 A3 WO 2007146761A3 US 2007070676 W US2007070676 W US 2007070676W WO 2007146761 A3 WO2007146761 A3 WO 2007146761A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
pyrimidinones
diaryl
compounds
related compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/070676
Other languages
English (en)
Other versions
WO2007146761A2 (fr
Inventor
Hongbin Li
Jun Yuan
David J Wustrow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurogen Corp
Original Assignee
Neurogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corp filed Critical Neurogen Corp
Publication of WO2007146761A2 publication Critical patent/WO2007146761A2/fr
Publication of WO2007146761A3 publication Critical patent/WO2007146761A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés répondant à la Formule (I), les variables étant telles que décrites dans ce document. De tels composés peuvent être utilisés pour moduler l'activité du CB 1 in vivo ou in vitro, et ils se révèlent particulièrement utiles pour le traitement de pathologies sensibles à la modulation du CB 1 chez les êtres humains, les animaux de compagnie et les animaux d'élevage, y compris les troubles de l'appétit, l'obésité et les troubles de dépendance. L'invention concerne également des compositions pharmaceutiques et des procédés permettant de les utiliser en vue de traiter lesdits troubles, de même que des procédés destinés à utiliser de tels ligands pour des études de localisation des récepteurs et des essais variés in vitro.
PCT/US2007/070676 2006-06-12 2007-06-08 Diaryl pyrimidinones et composés associés Ceased WO2007146761A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80445106P 2006-06-12 2006-06-12
US60/804,451 2006-06-12

Publications (2)

Publication Number Publication Date
WO2007146761A2 WO2007146761A2 (fr) 2007-12-21
WO2007146761A3 true WO2007146761A3 (fr) 2008-10-30

Family

ID=38832696

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/070676 Ceased WO2007146761A2 (fr) 2006-06-12 2007-06-08 Diaryl pyrimidinones et composés associés

Country Status (1)

Country Link
WO (1) WO2007146761A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
FR2938537B1 (fr) * 2008-11-14 2012-10-26 Sanofi Aventis Derives de carbamates d'alkyl-heterocycles, leur preparation et leur application en therapeutique.
EP2404902A1 (fr) 2009-03-05 2012-01-11 Shionogi&Co., Ltd. Dérivés de la pipéridine et de la pyrrolidine dotés d'un antagonisme pour les récepteurs npy y5
KR101859409B1 (ko) 2009-10-23 2018-05-18 얀센 파마슈티카 엔.브이. 오렉신 수용체 조절제로서의 이치환된 옥타하이드로피롤로［3,4-ｃ］피롤
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
EP2582709B1 (fr) 2010-06-18 2018-01-24 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
JPWO2012011592A1 (ja) * 2010-07-23 2013-09-09 武田薬品工業株式会社 複素環化合物およびその用途
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
EP2760862B1 (fr) 2011-09-27 2015-10-21 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
EP3187492A4 (fr) * 2014-08-29 2018-05-09 The University of Tokyo Dérivé de pyrimidone ayant une activité inhibitrice de l'autotaxine
US10183949B2 (en) 2014-08-29 2019-01-22 The University Of Tokyo Pyrimidinone derivative having autotaxin-inhibitory activity
PT3426251T (pt) 2016-03-10 2022-07-27 Janssen Pharmaceutica Nv Métodos de tratamento da depressão utilizando antagonistas dos recetores de orexina-2

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007118149A2 (fr) * 2006-04-07 2007-10-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical Lollege Thiazole et thiophene analogues et leur utilisation pour traiter des maladies auto-immunes et des cancers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007118149A2 (fr) * 2006-04-07 2007-10-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical Lollege Thiazole et thiophene analogues et leur utilisation pour traiter des maladies auto-immunes et des cancers

Also Published As

Publication number Publication date
WO2007146761A2 (fr) 2007-12-21

Similar Documents

Publication Publication Date Title
WO2007146761A3 (fr) Diaryl pyrimidinones et composés associés
WO2006049941A3 (fr) Diaryl urees, antagonistes du cb1
TW200716594A (en) Substituted heteroaryl CB1 antagonists
WO2006078992A3 (fr) Analogues de piperazinyl-pyridine à substitution hétéroaryle
WO2007140383A3 (fr) Sulfonamides spirocycliques et composés apparentés
WO2009012482A3 (fr) Amides heterocycliques a 5 chainons et composes associes
MY150731A (en) Heteroaryl amide derivatives
WO2005007648A3 (fr) Analogues de biaryl piperazinyl-pyridine
WO2007101007A3 (fr) Heterocycles sulfonyl aryliques
MY148461A (en) Heteroaryl amide analogues as p2x7 antagonists
WO2008016811A3 (fr) Aminopipéridines et composés apparentés
WO2008024433A3 (fr) Dérivés de la pyrimidinone substitués par un halogénoalkyle
WO2005007652A3 (fr) Analogues de quinoline-4-ylamine substituee
WO2005110982A3 (fr) Analogues substitues 1-benzyl-4-substitues piperazine
WO2006026135A3 (fr) Analogues de biaryle pipérazinyl-pyridine substitués
WO2006052542A3 (fr) Urees arylalkyle utilisees comme antagonistes cb1
WO2008024438A3 (fr) Analogues de la 2-phénoxypyrimidinone
WO2008066664A3 (fr) Dérivés de pyrimidinone substitués par cis-cyclohexyle
WO2008033739A3 (fr) Dérivés de benzimidazolecarboxamide
WO2006076646A3 (fr) Analogues de quinolin-4-ylamine à substitution hétéroaryle
WO2006081388A3 (fr) Analogues de pyridazinyl-et de pyrimidinyl-quinolin-4-ylamine substitues
WO2007133820A3 (fr) Diaryl triazolones comme antagonistes de cb1
WO2006042289A3 (fr) Analogues de biaryl quinoline-4-ylamine a substitution
WO2005084401A3 (fr) Analogues des purines à substitution aryle
WO2008070014A3 (fr) Pipéridines à substitution cétonique de biaryle

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07798267

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07798267

Country of ref document: EP

Kind code of ref document: A2